Alexion Pharmaceuticals Executives
Alexion Pharmaceuticals employs about 3.8 K people. The company is managed by 33 executives with a total tenure of roughly 301 years, averaging almost 9.0 years of service per executive, having 116.27 employees per reported executive. Analysis of Alexion Pharmaceuticals' management performance can provide insight into the firm performance.
| Ludwig Hantson CEO CEO, Director |
| Leonard Bell CEO CEO, Treasurer, Director |
Alexion |
Alexion Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 10.08 % which means that it generated a profit of $10.08 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on stockholder's equity (ROE) of 4.43 %, meaning that it created $4.43 on every $100 dollars invested by stockholders. Alexion Pharmaceuticals' management efficiency ratios could be used to measure how well Alexion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Alexion Pharmaceuticals Workforce Comparison
Alexion Pharmaceuticals is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is presently estimated at about 177,033. Alexion Pharmaceuticals holds roughly 3,837 in number of employees claiming about 2.17% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 10.89 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 52.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of $52.12. Alexion Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alexion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alexion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Alexion Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Carsten Thiel over a year ago Sale by Carsten Thiel of 1000 shares of Alexion Pharmaceuticals |
Alexion Pharmaceuticals Notable Stakeholders
An Alexion Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alexion Pharmaceuticals often face trade-offs trying to please all of them. Alexion Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alexion Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ludwig Hantson | CEO, Director | Profile | |
| Leonard Bell | CEO, Treasurer, Director | Profile | |
| David Hallal | CEO and Director | Profile | |
| Edward Miller | Senior Vice President Global Chief Compliance Officer | Profile | |
| Dominique Monnet | Senior Vice President Chief Marketing Officer | Profile | |
| Saqib Islam | Senior Vice President Chief Strategy and Portfolio Officer | Profile | |
| John Orloff | Executive Vice President Head of Research and Development | Profile | |
| Vikas Sinha | CFO, Executive Vice President | Profile | |
| Julie ONeill | Executive Vice President - Global Operations | Profile | |
| Clare Carmichael | Chief Human Resource Officer, Senior Vice President | Profile | |
| Ellen Chiniara | Executive Vice President General Counsel, Corporate Secretary | Profile | |
| Heidi Wagner | Senior Vice President - Global Governmental Affairs | Profile | |
| AnneMarie Law | Chief Patient and Employee Experience Officer, Executive Vice President | Profile | |
| Indrani Franchini | Executive Vice President Chief Compliance Officer | Profile | |
| John Moriarty | Senior Vice President General Counsel | Profile | |
| Carsten Thiel | Senior Vice President EMEA and Asia Pacific | Profile | |
| David Anderson | CFO | Profile | |
| Paul Clancy | CFO | Profile | |
| Martin Mackay | Global Head of RandD and Executive VP | Profile | |
| Felix Baker | Director | Profile | |
| Andreas Rummelt | Independent Director | Profile | |
| Deborah Dunsire | Independent Director | Profile | |
| Paul Friedman | Director | Profile | |
| Christopher Coughlin | Independent Director | Profile | |
| Ann Veneman | Independent Director | Profile | |
| Francois Nader | Director | Profile | |
| Judith Reinsdorf | Director | Profile | |
| Alvin Parven | Independent Director | Profile | |
| Michele Burns | Independent Director | Profile | |
| Douglas Norby | Lead Independent Director | Profile | |
| David Brennan | Independent Director | Profile | |
| John Mollen | Director | Profile | |
| Brian Goff | Chief Commercial Officer | Profile |
Alexion Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Alexion Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alexion Pharmaceuticals within its industry.Alexion Pharmaceuticals Manpower Efficiency
Return on Alexion Pharmaceuticals Manpower
| Revenue Per Employee | 1.6M | |
| Revenue Per Executive | 189.7M | |
| Net Income Per Employee | 177.7K | |
| Net Income Per Executive | 20.7M | |
| Working Capital Per Employee | 444.9K | |
| Working Capital Per Executive | 51.7M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Alexion Stock
If you are still planning to invest in Alexion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alexion Pharmaceuticals' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |